PO BOX 2544 


© 2019 Ryan's Quest       501(c) (3)Documentation

(609) 947-3611

April 9, 2015

Cleveland and Columbus, OH, April 9, 2015—Milo Biotechnology announced the first Duchenne muscular dystrophy (DMD) patient was treated with follistatin gene therapy at Nationwide Children’s Hospital. The therapy, delivered by intramuscular injection, is designed to maintain or restore muscle function in boys affected with DMD. This six patient clinical trial follows from a trial of the therapy in Becker muscular dystrophy pati...

Please reload

Please reload

Recent Posts
Search By Tags